^
    10d
    NeoGenomics Launches RaDaR ST, Expanding Molecular Residual Disease Testing Across Multiple Solid Tumor Types (NeoGenomics Press Release)
    "NeoGenomics...today announced the launch of RaDaR® ST, its circulating tumor DNA (ctDNA) assay for detecting molecular residual disease (MRD)."
    Launch
    |
    RaDaR® ST